(509) 228-1000 WA
(208) 754-3100 ID

Coronavirus (COVID-19) Update: Get the latest information on how we’re responding to the novel coronavirus (COVID-19). CLICK HERE »

Srivalli Gopaluni, MD

Share

back to doctor information

Specialty

Medical Oncology and Hematology

Optune (Tumor Treatment Fields for GBM)

Location:

NORTH SPOKANE

Dr. Sri Gopaluni participates in the care of a broad spectrum of hematological and malignant disorders. She has a special interest in Benign Hematology, Hematologic Malignancies, Breast, Lung and Gastrointestinal Oncology. She is very enthused about the new treatments in Melanoma and GU Oncology and has a special interest in enrolling patients on clinical trials. Medical Ethics and Clinical Research are other areas of active interest. Dr. Gopaluni believes in going the extra mile in patient care with a strong philosophy of “Patient First.”  

Clinical Trials

TRIAL NUMBER - NCT03906071

A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE).

TRIAL NUMBER - NCT04199104

A Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) to evaluate the safety and efficacy of pembrolizumab and lenvatinib as 1L intervention in a PD-L1 selected population of participants with recurrent or metastatic head and neck squamous cell carcinoma.

TRIAL NUMBER - NCT03833154

A Phase 3, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515).